Each month, Clinical Advisor makes one new clinical feature available ahead of print. Don’t forget to take the poll. The results will be published in the next month’s issue. Each year there are 3.9 ...

High doses of erythropoiesis-stimulating agents were associated with an increased risk for cancer in patients on dialysis, but the real risk attributed to these medications remains unclear.

Mobile screening for kidney disease may be a valuable tool in improving population health and identifying at-risk patients, ...

CKD complicates cancer treatment, reducing adjuvant chemotherapy use and increasing mortality risk, necessitating individualized treatment approaches. In a study of 109,875 cancer patients, only 42% ...

A recent case study found a possible new trigger for a dangerous, and sometimes fatal, virus that could be laying dormant in ...

Colored x-ray of the pelvic region shows a fractured femur (red) caused by a fall. A lack of clinical trials and limited pharmaceutical options mean that management of this complication poses ...

Among patients with CKD, serum total ALP and its liver, bone, and intestinal fractions increase with disease severity, and ...

Patients with chronic kidney disease (CKD) are no more likely to be included in trials of medications aimed at reducing cardiovascular risks now than they were about two decades ago, resulting in ...

Good sources of zinc include oysters. Inflammation and oxidative stress are two etiologies that may contribute to poor nutritional status and ultimately increased mortality rates in patients with ...

Chronic kidney disease patients living in the hottest countries experienced an additional 8% drop in kidney function each year compared to those living in temperate climates, finds a new study from ...

KERENDIA is a non-steroidal mineralocorticoid receptor antagonist (nsMRA) that selectively and potently blocks mineralocorticoid receptor overactivation in the heart and kidneys. 2 FIND-CKD is the ...

Findings from the FIND-CKD trial indicate finerenone may provide a new treatment option for slowing renal function loss in CKD patients without diabetes.